Education
About Us
Working with TipRanks
Follow Us
Intellia Therapeutics (DE:38I)
FRANKFURT:38I
Earnings Data
Report Date
Apr 30, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.78Last Year’s EPS
-0.94Same Quarter Last Year
Moderate Buy
Based on 17 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presents a mix of important clinical and commercial progress — most notably the completed Phase 3 enrollment and upcoming pivotal readout for lonvo-z, strong patient and physician interest, durable early efficacy signals, and improved near-term financial metrics — alongside meaningful risks: a still-pending FDA hold on the large cardiomyopathy ATTR program driven by serious liver enzyme events (including one patient death), material year-over-year cash depletion, and incomplete understanding of the safety signal’s mechanism and breadth. Management has secured a partial regulatory win (MAGNITUDE-2 hold lifted with specific mitigations) and emphasizes preparedness for a potential lonvo-z launch, but the unresolved MAGNITUDE hold and safety uncertainty inject non-trivial downside risk.Company Guidance
Lonvo-z Phase 3 Enrollment and Imminent Readout
Completed enrollment of the HAELO Phase 3 trial with 80 patients in ~9 months; top-line data expected by mid-2026 and a planned BLA submission in H2 2026 — positioning Intellia for the world’s first pivotal readout for an in vivo CRISPR gene-editing therapy.
Strong Patient and Physician Demand for Lonvo-z
Market research: 99% of surveyed U.S. HAE patients were at least somewhat likely to take the gene-editing treatment (nearly two-thirds extremely/very likely); 92% of 151 U.S. HCPs said they could identify a patient to prescribe to — providers collectively manage >4,000 patients (≈60% of treated U.S. population) and indicated ~2,200 (54%) could be prescribed lonvo-z.
Durable Clinical Signals in Early Studies
With up to three years of follow-up in Phase 1/2 studies, no waning of serum kallikrein or TTR reductions was observed; pooled analysis showed 76% of patients ≥1 year beyond a 50 mg lonvo-z dose were free from attacks and ongoing therapy for ≥12 months.
Financial Improvements in Q4 2025
Q4 collaboration revenue rose to $23.0M from $12.9M (+~78% YoY); R&D expense decreased to $88.7M from $116.9M (≈-24% YoY); net loss narrowed to $95.8M from $128.9M (≈-26% YoY).
Cash Runway and Commercial Readiness
Cash, cash equivalents and marketable securities were $605.1M as of Dec 31, 2025 (down from $861.7M a year earlier, ≈-30%), which management expects is sufficient to reach into the second half of 2027 and through key milestones; CMC and commercial preparedness for lonvo-z described as largely complete, with commercial field teams and payer engagement underway.
Regulatory Progress on MAGNITUDE-2 (PN)
FDA lifted the clinical hold on MAGNITUDE-2 (polyneuropathy) in late January 2026 after agreeing to study modifications (additional early post-dose liver labs, short-term steroid regimen for LFT elevations, and modified screening criteria); target enrollment increased from 50 to ~60 and 47 patients were already enrolled.
DE:38I Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:38I Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 26, 2026 | €11.45 | €12.00 | +4.80% |
Nov 06, 2025 | €11.77 | €8.11 | -31.03% |
Aug 07, 2025 | €9.73 | €10.20 | +4.82% |
May 08, 2025 | €6.35 | €7.35 | +15.78% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Intellia Therapeutics (DE:38I) report earnings?
Intellia Therapeutics (DE:38I) is schdueled to report earning on Apr 30, 2026, TBA (Confirmed).
What is Intellia Therapeutics (DE:38I) earnings time?
Intellia Therapeutics (DE:38I) earnings time is at Apr 30, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Intellia Therapeutics stock?
The P/E ratio of Intellia Therapeutics is N/A.
What is DE:38I EPS forecast?
DE:38I EPS forecast for the fiscal quarter 2026 (Q1) is -0.78.